TCM
JAZZ icon

Triumph Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Triumph Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$481K Buy
+2,545
New +$445K 0.1% 191

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Triumph Capital Management's JAZZ Position: Q1 2026 in Review

Triumph Capital Management opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 2,545 shares worth $481K. The stake represents 0.1% of the portfolio and ranks #191 among its holdings.

570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Triumph Capital Management held 2,545 shares of Jazz Pharmaceuticals worth $481K as of Q1 2026.
  • Jazz Pharmaceuticals was a new Triumph Capital Management position in Q1 2026.
  • Jazz Pharmaceuticals made up 0.1% of Triumph Capital Management's portfolio in Q1 2026, its #191 holding.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Triumph Capital Management's 13F filing for Q1 2026, filed 13 May 2026.